Developing new antimicrobial therapies to treat resistant Gram-negative infections
cUTI: complicated Urinary Tract Infection; MDR: multi-drug resistant; ESBL: extended spectrum beta-lactamases.
Only ZEMDRI has been approved for commercial use. See full Prescribing Information. All other product candidates are investigational only, potential treatments, and have not been approved for commercial use.